SOLUTION / PUBLIC SOURCE RECORD
NextPharma Asker chewable tablets help maintain bone health
- Published November 10, 2025; updated March 23, 2026; estimated reading time 3 minutes. Available across the Americas, Europe and Asia. Category: Health and life science / Biopharma.
- NextPharma Asker develops and manufactures chewable tablets for food supplements, OTC products and prescription medicines. Products include calcium, vitamin D3 and vitamin K2 supplements and calcium-carbonate antacids. The site is described as a chewable-tablet centre of excellence that can produce other tablet types. Products come in multiple strengths and flavours, including lemon, orange, spearmint and strawberry/watermelon, and are described as affordable, easy to take and pleasant to chew.
- Production uses pharmaceutical-grade materials and processes under EU GMP and Eurasian Economic Union GMP standards. Products may be marketed as supplements, OTC medicines or prescription products depending on local rules. The automated site follows lean manufacturing and can make medium to large batches up to 4 metric tonnes. Services include commercial production and packaging, product development and improvement, stability testing, scale-up, quality control, process validation and regulatory documentation.
- The article says calcium supports bone density and strength, vitamin D3 improves calcium absorption and supports immune function, and vitamin K2 directs calcium toward bones and teeth while limiting accumulation in blood vessels. The company says it uses green energy and has been carbon neutral since 2025.
- Market context: the global calcium-supplement market is valued at USD 6.19 billion in 2025 and forecast to reach USD 9.22 billion by 2035, with demand linked to bone-health awareness among older people and women at risk of osteoporosis or post-menopausal bone-density loss. NextPharma Asker exports over 95% of production to 45 countries and cites over 110 years of Norwegian production experience. SDGs 3 and 9 shown.
- Contact: Bjørn Lie, Managing Director, Bjorn.Lie@nextpharma.com; phone reveal control collapsed. Company: ASKER CONTRACT MANUFACTURING AS, Drammensveien 852, 1383 Asker, Norway; nextpharma.com/.